Professur für Tumorimmunologie (Schwerpunkt Systembiologie)

Multi-level cancer profiling through joint cell-graph representations (2024) Rivera Monroy LC, Rist L, Wilm F, Ostalecki C, Baur A, Vera González J, Breininger K, Maier A Journal article Comparative Analysis of Radiomic Features and Gene Expression Profiles in Histopathology Data using Graph Neural Networks (2024) Rivera Monroy LC, Rist L, Eberhardt M, Ostalecki C, Bauer A, Vera J, Breininger K, Maier A Conference contribution Identifizierung von Biomarkern und neuen therapeutischen Zielen beim Aderhautmelanom (2024) Wessely A, Koch E, Vera J, Berking C, Heppt M Journal article Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity (2024) Wang Y, Ertl C, Schmitt C, Hammann L, Kramer R, Grabmaier U, Schöberl F, et al. Journal article Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms (2024) Winter S, Schneider M, Oelschlaegel U, Maggioni G, Riva E, Raddi MG, Bencini S, et al. Journal article Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid (2024) Kramer N, Müller G, Zierold S, Röckel M, Fröhlich W, Schefzyk M, Kumbrink J, et al. Journal article, Letter E2F1-induced autocrine IL-6 inflammatory loop mediates cancer-immune crosstalk that predicts T cell phenotype switching and therapeutic responsiveness (2024) Spitschak A, Dhar P, Singh KP, Garduño RC, Gupta SK, Vera J, Musella L, et al. Journal article Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab. (2024) Biedermann A, Patra-Kneuer M, Mougiakakos D, Büttner-Herold M, Mangelberger-Eberl D, Berges J, Kellner C, et al. Journal article Employing Graph Representations for Cell-Level Characterization of Melanoma MELC Samples (2023) Rivera Monroy LC, Rist L, Eberhardt M, Ostalecki C, Baur A, Vera J, Breininger K, Maier A Conference contribution Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy (2023) Reimann H, Kremer A, Blumenberg V, Schmidt K, Aigner M, Jacobs B, Eisenhauer N, et al. Journal article, Letter